Iressa Survival Study Is Ahead Of Schedule; Tarceva Trial Is "Good News"
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca plans to meet with FDA and clinical investigators to discuss the progress of a lung cancer survival study of Iressa (gefitinib) once it sees the "details" of a study showing improved survival in patients treated with Genentech/OSI's Tarceva (erlotinib)